Citius Oncology Inc (Nasdaq:CTOR), the oncology-focused subsidiary of biopharmaceutical company Citius Pharmaceuticals Inc (Nasdaq:CTXR), announced on Wednesday that it has signed a distribution agreement with Uniphar, an international healthcare services company based in Ireland, to support access to LYMPHIR (denileukin diftitox-cxdl) outside the United States.

This agreement represents Citius Oncology's third international distribution partnership, and further advances its strategy to expand global access to LYMPHIR through established regional partners.

LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), indicated for use in Stage I-III disease after at least one prior systemic therapy.

Uniphar will serve as the exclusive distribution partner for LYMPHIR in designated international territories in Western and Eastern Europe through country-specific managed access programmes, where permitted by local law. Citius Oncology will supply finished product and provide ongoing support.

LYMPHIR is not approved for commercial use outside the United States and, where permitted by local law, will be provided in the territories covered by this agreement solely through country-specific managed access programmes, which do not constitute marketing authorisation or a commercial launch.